Be among trailblazing marketing pros at Brandweek this September 23–26 in Phoenix, Arizona. Experience incredible networking, insightful sessions and a boost of inspiration at ADWEEK’s ultimate brand event. Register by May 13 to save 35%.
Advertising trade groups are bracing for a fight as lawmakers threaten to dampen what has become a $2 billion-plus market in the five years since federal law opened up direct-to-consumer advertising to drug companies.
One lawmaker earlier this month introduced a bill to curb pharmaceutical ad vertising, and another has vowed to revive efforts to introduce similar legislation that was defeated last year.
When this year began, lobby groups were breathing a little easier about the prospects for anti-drug-ad legislation, hoping that new Senate majority leader Bill Frist, R-Tenn.,
WORK SMARTER - LEARN, GROW AND BE INSPIRED.
Subscribe today!
To Read the Full Story Become an Adweek+ Subscriber
Already a member? Sign in